Lipid lowering Effect of Dapagliflozin Alone versus Dapagliflozin- Saxagliptin Combination in Type 2 Diabetes (T2DM) Subjects

Effect of Dapagliflozin (Dapa) and Dapagliflozin-Saxagliptin combination (Combo) were examined on lipid parameters and inflammatory markers, pre and post therapy. Both Dapa (a SGLT2 receptor inhibitor) and Saxagliptin (a DPP4 enzyme inhibitor) are type 2 diabetes (T2DM) meds, but the combination has not been evaluated for cardiometabolic risk stratification. We hypothesized that Dapa will improve the outcomes when compared to placebo. We also postulated that the Combination of Dapagliflozin+Saxagliptin maybe even more efficient in lipid lowering compared to Dapagliflozin alone.
Source: Journal of Clinical Lipidology - Category: Lipidology Authors: Tags: Lipid Management through Pharmacology Source Type: research